Syros Pharmaceuticals Inc (LTS:0LC7)
$ 0.2 0 (0%) Market Cap: 5.44 Mil Enterprise Value: 7.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 18/100

Q1 2023 Syros Pharmaceuticals Inc Earnings Call Transcript

May 10, 2023 / 12:30PM GMT
Release Date Price: $3.55 (+11.57%)
Operator

Good morning, and welcome to Syros Pharmaceuticals' First Quarter 2023 Financial Results Conference Call. (Operator Instructions) This call is being webcast live on the Investors and Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded.

At this time, I would like to turn the call over to Karen Hunady, Director of Investor Relations and Corporate Communications at Syros.

Karen Hunady
Syros Pharmaceuticals, Inc. - Director of Corporate Communications & IR

Thank you. This morning, we issued a press release announcing our first quarter 2023 financial results and business update. The full release is available on the Investor and Media section of Syros' website at www.syros.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Jason Haas, our Chief Financial Officer. We will then open the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot